Adlai Nortye Ltd. Sponsored ADR

ANL Healthcare Biotechnology

Adlai Nortye Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.0 million, roughly unchanged from fiscal 2023. Dividend growth for five consecutive years.

11.07 1.02 −8.44%
Market cap
$710.1M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−22.05
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Altman Z-Score
(22.05) — (3.97) — —
Altman Z″-Score (non-manufacturers)
(53.99) — (9.17) — (0.91)
P/FCF ratio
0.00 — 0.00 — 0.00
P/Operating CF
0.00 — 0.00 — 0.00
P/B ratio
0.00 — 0.00 — 0.00
EV/Sales
0.00 — 0.00 — 0.00
EV/EBITDA
0.00 — 0.00 — 0.00
EV/FCF
(0.01) — 0.00 — 0.00
Current Ratio
0.65 1.41 2.04 0.21 7.12
Net Debt/EBITDA
(0.05) 0.66 0.95 0.88 13.57
Debt/Equity
(3.09) 1.05 0.41 (0.02) (0.07)
ROE
(414.01%) (103.19%) 123.26% 26.21% 0.00%
ROA
(67.22%) (51.49%) (107.73%) (57.56%) 0.00%
ROIC
0.00% 0.00% (615.01%) 0.00% 0.00%
Return on Tangible Assets
262.84% (253.68%) (201.65%) 24.23% (51.20%)
Average Days of Receivables
0.00 — 0.00 — 0.00
Free Cash Flow Yield
0.00% — 0.00% — 0.00%
Free Cash Flow per Share
(1.05) (1.63) (3.94) (5.24) (0.49)
Book value per Share
(0.26) 0.80 5.19 (28.45) (21.87)
Free Cash Flow
(33.64) (51.96) (56.85) (44.47) (4.15)
EV/EBIT
0.00 — 0.00 — 0.00
Other line items

Show all line items

Columns are period end dates